Silexion Therapeutics (NASDAQ:SLXN) Trading Down 7.2% – Here’s Why

Shares of Silexion Therapeutics Corp (NASDAQ:SLXN) traded down 7.2% during trading on Friday . The stock traded as low as $2.48 and last traded at $2.58. Approximately 7,291 shares traded hands during trading, a decline of 85% from the average session volume of 47,613 shares. The stock had previously closed at $2.78.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold”.

Silexion Therapeutics Stock Performance

The business’s fifty day moving average price is $3.56 and its 200-day moving average price is $11.24. The stock has a market cap of $1.08 million, a PE ratio of -0.03 and a beta of -0.26.

Silexion Therapeutics (NASDAQ:SLXN) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($12.90) by $12.05. Analysts forecast that Silexion Therapeutics Corp will post -45.5 earnings per share for the current fiscal year.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.